MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety DisordersPRNewsWire • 05/11/22
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business UpdatePRNewsWire • 05/09/22
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH SymposiumPRNewsWire • 04/14/22
Mind Medicine (MindMed) Inc. (MNMD) CEO Rob Barrow on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/28/22
MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business UpdatePRNewsWire • 03/21/22
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy SubjectsPRNewsWire • 03/02/22
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.Benzinga • 02/14/22
MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 YearsBenzinga • 01/26/22
MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric TodayInvestorPlace • 01/25/22